又一重磅License-out，医药出海驶入深水区，行业大咖这样支招

Core Insights - The collaboration between Innovent Biologics and Eli Lilly aims to advance global R&D in oncology and immunology, with Innovent receiving an upfront payment of $350 million and potential milestone payments and sales shares totaling up to $8.5 billion [1][6] - The partnership between Junshi Biosciences and Japan's Eisai for the development and commercialization of a cancer treatment in Japan is valued at nearly $400 million [1][6] - By 2025, the total value of China's innovative drug licensing-out transactions is expected to exceed $130 billion, indicating a significant trend towards internationalization among Chinese pharmaceutical companies [7][8] Industry Trends - The internationalization of Chinese pharmaceutical companies is characterized by a dual structure, where leading firms like China Resources Pharmaceutical and BeiGene have established a solid international foundation, while many small and medium-sized enterprises view overseas markets as new opportunities due to intense domestic competition [7][8] - The current internationalization process is described as "building a ship while sailing," with many companies lacking a clear understanding of overseas market regulations, payment mechanisms, and competitive landscapes [2][7] Macro Environment - China's pharmaceutical industry is projected to maintain stable growth by 2025, contributing 20% of new drugs globally, second only to the U.S. [8][9] - The number of clinical trial applications submitted by Chinese companies to international bodies is on the rise, reflecting increased engagement in global drug development [9] Definition of Internationalization - True internationalization goes beyond mere export trade; it involves deep integration and coordination of products, services, technologies, and resources on a global scale [3][9] - Key criteria for a company to be considered "internationalized" include having over 50% of revenue from overseas sales, more than 50% of non-national employees, and a product pipeline designed for global markets [3][9] Characteristics of Internationalization - The internationalization of China's pharmaceutical industry exhibits six main characteristics: stable trade fundamentals, high willingness to expand abroad but lacking experience, diverse target markets, accelerated compliance processes, an emerging support ecosystem, and a shortage of qualified international talent [10][11] - Many companies still design their product pipelines primarily for the Chinese market, which can lead to challenges in meeting international market demands [10][11] Compliance and Talent Challenges - Compliance capability is essential for internationalization, especially for companies entering high-end medical devices and biopharmaceuticals, which must meet international regulatory standards [11][12] - There is a critical shortage of professionals with the necessary skills in regulatory affairs, global strategy, and cross-cultural communication, which hampers deeper integration into the global pharmaceutical ecosystem [11][12] Integration into Global Networks - Chinese companies have not fully integrated into the global pharmaceutical industry's core collaborative networks, which are often dominated by Western firms [12] - Successful internationalization requires not only market entry but also meaningful integration into global innovation and manufacturing circles to access cutting-edge technologies and patents [12]